Gene symbol | CXCL10 | Synonyms | C7, IFI10, INP10, IP-10, SCYB10, crg-2, gIP-10, mob-1 | Type of gene | protein-coding |
Chromosome | 4 | Map location | 4q21.1 | dbXrefs | |
Description | C-X-C motif chemokine ligand 10 |
Gene symbol | CXCL9 | Synonyms | CMK, Humig, MIG, SCYB9, crg-10 | Type of gene | protein-coding |
Chromosome | 4 | Map location | 4q21.1 | dbXrefs | |
Description | C-X-C motif chemokine ligand 9 |
Gene symbol | FAP | Synonyms | DPPIV, FAPA, FAPalpha, SIMP | Type of gene | protein-coding |
Chromosome | 2 | Map location | 2q24.2 | dbXrefs | |
Gene perturbation-related omics dataset | PerturbAtlas | ||||
Description | fibroblast activation protein alpha |
Gene symbol | IFNA2 | Synonyms | IFN-alpha-2, IFN-alphaA, IFNA, IFNA2B, leIF A | Type of gene | protein-coding |
Chromosome | 9 | Map location | 9p21.3 | dbXrefs | |
Description | interferon alpha 2 |
GTO ID | GTC4007 |
Trial ID | NCT04830592 |
Disease | Head and Neck Squamous Cell Carcinoma |
Altered gene | E1A|E1B|FAP|CXCL9|CXCL10|IFNA2 |
Therapeutic/Target gene | Therapeutic gene |
Therapy | DNA oncolytic virus |
Treatment | NG-641 |
Phase | Phase1 |
Recruitment status | Active, Not Recruiting |
Title | A Multicentre, Open-label, Dose-escalating, Phase Ib, Study of Intravenous Dosing of NG-641, as Monotherapy or in Combination With Pembrolizumab in Patients With Surgically Resectable Squamous Cell Carcinoma of the Head and Neck |
Year | 2021 |
Country | United Kingdom |
Company sponsor | Akamis Bio |
Other ID(s) | NG-641-02 |
Vector information | |||||||
|
Cohort1: NG-641 | |||||||
|
|||||||
Cohort2: NG-641_Pembrolizumab | |||||||
|